Sal Trading, LLC Argenx Se Call Options Transaction History

Sal Trading, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $347,376 - $441,520	800 Added 160.0%	1,300 $705,000
Q2 2024 Aug 15, 2024	SELL	$356.01 - $451.55 $4.13 Million - $5.24 Million	-11,600 Reduced 95.87%	500 $215,000
Q1 2024 May 07, 2024	SELL	$356.95 - $413.29 $2.28 Million - $2.65 Million	-6,400 Reduced 34.59%	12,100 $4.76 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $5.96 Million - $8.91 Million	-17,600 Reduced 48.75%	18,500 $7.04 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $11.9 Million - $17.6 Million	32,100 Added 802.5%	36,100 $17.7 Million
Q2 2023 Aug 11, 2023	BUY	$360.14 - $422.58 $1.44 Million - $1.69 Million	4,000 New	4,000 $1.56 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $152,670 - $210,636	-600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $163,206 - $211,817	600 New	600 $210,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Sal Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Sal Trading, LLC with notifications on news.